COMPARISON OF MORTALITY IN PATIENTS ON CHEMOTHERAPY OR IMMUNOTHERAPY DURING AND BEFORE COVID-19 PANDEMIC. MULTICENTER MATCHED COHORT STUDY IN ARGENTINA.

Objectives. To compare all-cause mortality of unvaccinated oncology patients who received chemotherapy or immunotherapy during the pandemic with those treated before the pandemic. Materials and methods. We conducted a cohort study in four tertiary hospitals in Argentina. Outpatients with a solid neo...

Descripción completa

Detalles Bibliográficos
Publicado en:Revista Peruana de Medicina Experimental y Salud Pública Vol. 40; no. 2; pp. 161 - 170
Autores principales: Itkin, Boris, Straminsky, Samanta, Cáceres, Hernán, Onassis, Mariana, Emilio García, Agustín, Avanzi, Laura, Kaminszczik, Lucia, Serna Sejas, Richard, Rapaccioli, Mara, Billordo, Gustavo, Lavaccara, Damián, Lanzavecchia, Julián, Gibbons, Luz, Settecase, Eugenia, Bardach, Ariel
Formato: Artículo
Publicado: Instituto Nacional de Salud (Peru) 2023
Materias:
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=lth&AN=169960985&site=ehost-live
header:
  @attributes:
    shortDbName: lth
    uiTerm: 169960985
    longDbName: MedicLatina
    uiTag: AN
  controlInfo:
    bkinfo:
    jinfo:
      jid:
        17264634
        2WT0
      jtl: Revista Peruana de Medicina Experimental y Salud Pública
      issn: 17264634
      maglogo: N
    pubinfo:
      dt: 2023
      vid: 40
      iid: 2
      pid: 27380
      pub: Instituto Nacional de Salud (Peru)
    artinfo:
      ui:
        169960985
        10.17843/rpmesp.2023.402.12519
      ppf: 161
      ppct: 9
      formats:
        fmt:
          @attributes:
            type: P
            size: 519KB
      tig:
        atl: COMPARISON OF MORTALITY IN PATIENTS ON CHEMOTHERAPY OR IMMUNOTHERAPY DURING AND BEFORE COVID-19 PANDEMIC. MULTICENTER MATCHED COHORT STUDY IN ARGENTINA.
      aug:
        au:
          Itkin, Boris
          Straminsky, Samanta
          Cáceres, Hernán
          Onassis, Mariana
          Emilio García, Agustín
          Avanzi, Laura
          Kaminszczik, Lucia
          Serna Sejas, Richard
          Rapaccioli, Mara
          Billordo, Gustavo
          Lavaccara, Damián
          Lanzavecchia, Julián
          Gibbons, Luz
          Settecase, Eugenia
          Bardach, Ariel
        affil:
          Oncologist, master in Medical Molecular Biology, Hospital Juan A. Fernández, Buenos Aires, Argentina
          Oncologist, Hospital Juan A. Fernández, Buenos Aires, Argentina
          Oncologist, Sanatorio Luis Pasteur, Catamarca, Argentina
          Pediatric hematologist/oncologist, Sanatorio Luis Pasteur, Catamarca, Argentina
          Oncologist, Sanatorio Dr. Julio Méndez, Buenos Aires, Argentina
          Oncologist, Policlínico Modelo de Cipolletti, Rio Negro, Argentina
          Pulmonologist, Policlínico Modelo de Cipolletti, Rio Negro, Argentina
          Licentiate in Statistics, Center for Research in Epidemiology and Public Health (CIESP) Instituto de Efectividad Clínica y Sanitaria (IECSCONICET), Buenos Aires, Argentina
          Doctor of Public Health, Center for Research in Epidemiology and Public Health (CIESP) Instituto de Efectividad Clínica y Sanitaria (IECSCONICET), Buenos Aires, Argentina
      su:
        Mortality
        Cancer chemotherapy
        Immunotherapy
        COVID-19 pandemic
        Body mass index
      sug:
        subj:
          Mortality
          Cancer chemotherapy
          Immunotherapy
          COVID-19 pandemic
          Body mass index
      keyword:
        Cancer
        Chemotherapy
        Cohort Studies
        COVID-19
      ab: Objectives. To compare all-cause mortality of unvaccinated oncology patients who received chemotherapy or immunotherapy during the pandemic with those treated before the pandemic. Materials and methods. We conducted a cohort study in four tertiary hospitals in Argentina. Outpatients with a solid neoplasm of any stage under-going cytotoxic or intravenous immunotherapy were eligible. The pandemic cohort was enrolled during the initial phase of the outbreak and compared with a pre-pandemic cohort using propensity score matching (PSM). Subjects were matched for age, sex, health insurance, risk factors for severe COVID-19 complications, performance status, cancer type and treatment, line of treatment, and body mass index. All-cause mortality was estimated for both cohorts after 6 months of follow-up. Results. A total of 169 patients were recruited between April and August 2020 for the pandemic cohort and 377 for the pre-pandemic cohort in the same months of 2019; 168 patients were matched. After PSM, all-cause mortality was 17.9% in the pandemic cohort and 18.5% in the pre-pandemic cohort; the Relative Risk was 0.97 (95 % confidence interval: 0.61-1.52; p=0.888). In the pandemic cohort, 30/168 patients died, but none from COVID-19. Conclusions. Our findings show that the mortality rate of unvaccinated ambulatory patients on active intravenous oncology treatment during the COVID-19 pandemic did not increase.
      pubtype: Academic Journal
      doctype: Article
      src: R
    language: English
    refInfo:
    copyright:
      @attributes:
        flag: Y
      custom: Copyright of Revista Peruana de Medicina Experimental y Salud Pública is the property of Instituto Nacional de Salud (Peru) and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use.
      item: Revista Peruana de Medicina Experimental y Salud Pública
      holder: Instituto Nacional de Salud (Peru)
      dt:
        @attributes:
          year: 2023
    holdings:
      @attributes:
        islocal: N